ObjectiveTo investigate the effects of Yishen Juanbi pills （YSJB）-containing bone marrow fluid on the migration and differentiation phenotypes of CD4⁺T lymphocytes based on the stromal cell-derived factor-1/chemokine receptor 4 （SDF-1/CXCR4） signaling pathway. MethodsPrimary CD4⁺T lymphocytes were isolated from mice using magnetic bead separation and identified for purity by flow cytometry. A CD4⁺T lymphocyte culture system was then established to observe the effects of SDF-1 on CD4⁺T-cell migration and differentiation. On this basis， the experimental groups included the Sham group， the ovariectomy （OVX） group， the Sham+collagen-induced arthritis （CIA） group， the OVX+CIA group， the Sham+CIA+YSJB group （2.16 g·kg^-1）， the OVX+CIA+YSJB group （2.16 g·kg^-1）， and the OVX+CIA+methotrexate （MTX） group （1.5 mg·kg^-1）. Bone marrow fluid from each group was prepared according to previous methods and added to the CD4⁺ T-cell culture system at 5% （v/v）. Transwell assays were used to examine CD4⁺T-cell migration in each group. Real-time PCR was used to measure the mRNA expression levels of interleukin （IL）-17， tumor necrosis factor-α （TNF-α）， retinoic-acid-related orphan receptor γt （RORγt）， IL-10， transforming growth factor-β （TGF-β）， forkhead box P3 （FoxP3）， CXCR4， phosphoinositide 3-kinase （PI3K）， and protein kinase B （Akt）. Western blot was used to detect the expression of helper T （Th）17/regulatory T （Treg） cell signature factors （RORγt， FoxP3）， CXCR4， PI3K， phosphorylated （p）-PI3K， Akt， and p-Akt. In a separate set of experiments， cells were divided into the Sham group， OVX+CIA group， OVX+CIA+CXCR4 antagonist AMD3100 group， and OVX+CIA+YSJB+AMD3100 group to observe changes in the above indicators following AMD3100 intervention. ResultsCompared with the Sham group， the number of migrated cells in the lower chamber was significantly increased in the Sham+CIA and OVX+CIA groups （P<0.05， P<0.01）. The mRNA expression of RORγt， IL-17， TNF-α， CXCR4， PI3K， and Akt was significantly upregulated， whereas FoxP3， IL-10， and TGF-β mRNA expression was significantly decreased （P<0.05， P<0.01）. Protein expression of RORγt， CXCR4， p-PI3K/PI3K， and p-Akt/Akt was significantly increased， while FoxP3 protein expression was markedly decreased （P<0.05， P<0.01）. Compared with the OVX+CIA group， the OVX+CIA+YSJB group and OVX+CIA+MTX group showed significantly reduced migration （P<0.05）， mRNA expression of RORγt， IL-17， TNF-α， CXCR4， PI3K， and Akt was also significantly decreased， while FoxP3， IL-10， and TGF-β mRNA expression was significantly increased （P<0.05， P<0.01）. RORγt protein expression was significantly downregulated， and FoxP3 protein expression markedly upregulated （P<0.05）. In the OVX+CIA+YSJB group， CXCR4， p-PI3K/PI3K， and p-Akt/Akt protein expression was significantly decreased （P<0.05）. Compared with the OVX+CIA group， RORγt， CXCR4， PI3K， and Akt mRNA expression in CD4⁺T cells was significantly decreased in the OVX+CIA+AMD3100 group and the OVX+CIA+YSJB+AMD3100 group， while FoxP3 mRNA and protein expression was significantly upregulated （P<0.05， P<0.01）. RORγt， CXCR4， p-PI3K/PI3K， and p-Akt/Akt protein expression was also markedly decreased （P<0.05， P<0.01）. Compared with the OVX+CIA+AMD3100 group， the OVX+CIA+YSJB+AMD3100 group showed significantly decreased RORγt and Akt mRNA expression （P<0.05） and significantly lower p-Akt/Akt protein expression （P<0.05）. ConclusionYSJB-containing bone marrow fluid suppresses CD4⁺T-cell migration and regulates Th17/Treg balance by downregulating Th17-associated signature factors and upregulating Treg-associated signature factors through inhibition of the SDF-1/CXCR4 signaling pathway and PI3K/Akt signaling pathway. The SDF-1/CXCR4 signaling pathway is one of the targets through which YSJB inhibits CD4⁺T-cell differentiation.

The Pharmacovigilance Guideline for Clinical Application of Chinese Patent Medicine for External Use （T/CACM 1563.5—2024）， the first guideline in China specializing for the clinical safety of Chinese patent medicines for external use， was led by the Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences，and jointly developed by more than 30 research institutions of medical sciences across the country. Aiming to standardize the pharmacovigilance activities in the clinical application of Chinese patent medicines for external use，the guideline systematically categorizes potential risks and proposes prevention and control measures that cover 11 core sections of risk monitoring and reporting， signal identification，as well as assessment and control， addressing the gap in domestic and international standardization of this field. The compilation of this guideline strictly adhered to international norms and domestic regulations， involving multiple rounds of expert consultations，hybrid interviews， and evidence integration （covering literature，medical insurance，essential medicine，pharmacopoeia data， and regulatory information）. With the scope of application defined to include medical institutions， pharmaceutical manufacturers and distribution enterprises，as well as regulatory authorities， the guideline focuses on key issues such as inherent medicine risks，quality risks，off-label use，risks of combination therapy，and the safety in special populations. During the compilation，core discrepancies such as the definition of application scope and quality risk control were addressed to ensure alignment with regulations such as the Drug Administration Law of the People's Republic of China and the Good Pharmacovigilance Practice. The guideline is registered internationally （PREPARE—2022CN463）. In the future，the implementation of the guideline will be promoted through hierarchical dissemination，dynamic revision，and post-effectiveness evaluation， contributing to rational clinical use and improved patient safety.

The Pharmacovigilance Guideline for Clinical Application of Chinese Patent Medicine for External Use （T/CACM 1563.5—2024）， the first guideline in China specializing for the clinical safety of Chinese patent medicines for external use， was led by the Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences，and jointly developed by more than 30 research institutions of medical sciences across the country. Aiming to standardize the pharmacovigilance activities in the clinical application of Chinese patent medicines for external use，the guideline systematically categorizes potential risks and proposes prevention and control measures that cover 11 core sections of risk monitoring and reporting， signal identification，as well as assessment and control， addressing the gap in domestic and international standardization of this field. The compilation of this guideline strictly adhered to international norms and domestic regulations， involving multiple rounds of expert consultations，hybrid interviews， and evidence integration （covering literature，medical insurance，essential medicine，pharmacopoeia data， and regulatory information）. With the scope of application defined to include medical institutions， pharmaceutical manufacturers and distribution enterprises，as well as regulatory authorities， the guideline focuses on key issues such as inherent medicine risks，quality risks，off-label use，risks of combination therapy，and the safety in special populations. During the compilation，core discrepancies such as the definition of application scope and quality risk control were addressed to ensure alignment with regulations such as the Drug Administration Law of the People's Republic of China and the Good Pharmacovigilance Practice. The guideline is registered internationally （PREPARE—2022CN463）. In the future，the implementation of the guideline will be promoted through hierarchical dissemination，dynamic revision，and post-effectiveness evaluation， contributing to rational clinical use and improved patient safety.

On June 27， 2026， the Asian Pacific Association for the Study of the Liver （APASL） released updated management guidelines for chronic HBV infection， which systematically elaborates on screening， vaccination， antiviral treatment， and hepatocellular carcinoma surveillance and other aspects in 13 key areas， and provides comprehensive recommendations. This article summarizes and makes an excerpt of the key recommendations from the updated guidelines.

Background: and Purpose Vertebrobasilar fusiform aneurysms (VBFAs) carry substantial morbidity and mortality, but optimal management for unruptured VBFAs remains unclear. We compared the safety and efficacy of conservative management (CM), stent-assisted coiling (SAC), and flow diverters (FDs) in patients with unruptured VBFAs, focusing on long-term prognosis. Methods: This study included data from a nationwide Chinese cohort of patients with vertebrobasilar dissecting aneurysms. Inverse probability of treatment weighting (IPTW) balanced confounders across groups. The primary outcome was poor prognosis (modified Rankin Scale score >2). Secondary outcomes included aneurysm rupture, ischemic stroke, compression symptoms, and VBFA-related deaths. Logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs). Subgroup and sensitivity analyses were performed. Results: Among 1,115 patients with unruptured VBFAs, 838 (median age, 54 years; 655 men) were included. After IPTW, baseline characteristics were balanced. Median follow-up was 54 months. FD was associated with a lower risk of poor prognosis than CM (OR, 0.48 [95% CI, 0.30 to 0.77]; p=0.002), with no difference between CM and SAC. FD also reduced aneurysm rupture (OR, 0.20 [95% CI, 0.07 to 0.60]; p=0.004) and compression symptoms (OR, 0.30 [95% CI, 0.13 to 0.68]; p=0.004) versus CM. Time-to-event analyses further revealed significant differences in vertebral artery lesions and Type I–II VBFAs, whereas no significant differences were observed in basilar or vertebrobasilar junction lesions or in Type III–IV VBFAs. Conclusions Compared with CM, FD was associated with improved long-term outcomes in unruptured VBFAs, particularly in vertebral artery lesions and Type I–II VBFAs, although residual confounding cannot be excluded.

OBJECTIVE To explore the correlation between phosphatidylinositol-3-kinase alpha(PIK3CA)gene mutation and the clinicopathological characteristics of Epstein-Barr virus(EBV)infection in patients with gastric cancer.METHODS Cancer tissue samples were collected from 593 patients with gastric cancer who under-went surgery at the Affiliated Hospital of Hebei University between Sep.2021 and Sep.2024.EBV infection in pa-tients with gastric cancer was detected by EBV-encoded RNA(EBER)in situ hybridization.Based on the detec-tion results,patients were divided into an EBV-positive group(n=31)and an EBV-negative group(n=562).The incidence of EBV-infected gastric cancer was compared among patients of different genders and ages.The relationship between EBV infection and PIK 3CA gene mutation,as well as clinicopathological character-istics of patients with gastric cancer,was analyzed.Spearman's correlation analysis was used to assess the correla-tion between PIK3CA gene mutation and EBV infection in patients with gastric cancer.RESULTS Among the 593 gastric cancer cases,31 were EBER-positive,with a positive rate of 5.23％.EBER showed scattered dot scope or diffuse staining,appearing as a dark brown signal localized in the nucleus.The PIK3CA gene mutation rate was higher in the EBV-positive group(32.26％)than in the EBV-negative group(P＜0.001).PIK3CA gene muta-tions mainly occurred in exons 9 and 20,with 2 cases of p.E542K mutation,5 cases of p.E545K mutation,1 case of pH1047L mutation,no cases of p.H1047R mutation were detected.The proportion of patients with tumors at the esophagogastric junction,T3-T4 invasion depth,and lymph node metastasis was higher in the EBV-positive group than in the EBV-negative group(P＜0.05).There was a positive correlation between PIK 3CA gene muta-tion and EBV infection in patients with gastric cancer(r=0.742,P=0.026).The proportion of EBV infection was higher in male patients with gastric cancer(6.49％)than in females(P＜0.001).CONCLUSIONS The inci-dence of EBV-infected gastric cancer is low,but it is closely related to PIK3CA gene mutation,gender,tumor lo-cation,invasion depth and lymph node metastasis in patients with gastric cancer.

Objective To explore the changes in the levels of serum myocardial injury markers troponin I(cTNI),myoglobin(MYO),creatine kinase isoenzyme(CK-MB),and N-terminal pro-B natriuretic peptide precursor(NT-proBNP)in elderly patients with hypertension complicated with heart failure and their clinical value.Methods A total of 110 elderly patients with hypertension complicated with heart failure in the hospi-tal from February 2022 to February 2024 were selected as the hypertension complicated with heart failure group.During the same period,110 patients with simple heart failure were selected as the heart failure group,and 110 patients with simple hypertension were selected as the hypertension group.The levels of serum cTNI,MYO,CK-MB and NT-proBNP in each group were compared.Multivariate Logistic regression was used to an-alyze the influencing factors of hypertension complicated with heart failure.The receiver operating characteris-tic(ROC)curve was drawn to analyze the diagnostic efficacy of serum cTNI,MYO,CK-MB and NT-proBNP for hypertension complicated with heart failure.Results Compared with the hypertension group,the levels of serum cTNI,MYO,CK-MB and NT-proBNP in the hypertension combined with heart failure group and the heart failure group increased(P＜0.05);Compared with the heart failure group,the levels of serum MYO and NT-proBNP in the hypertension combined with heart failure group increased(P＜0.05).The results of multi-variate Logistic regression analysis showed that NT-proBNP was an independent influencing factor for hyper-tension complicated with heart failure(P＜0.05).The results of the ROC curve showed that the areas under the curve of serum cTNI,MYO,CK-MB,and NT-proBNP alone and in combination for the diagnosis of hyper-tension complicated with heart failure were 0.768,0.729,0.687,0.904,and 0.905,respectively.The sensitivi-ties were 96.4％,50.0％,79.1％,90.0％and 90.9％respectively,and the specificities were 54.1％,100.0％,60.0％,78.2％and 75.0％respectively.Conclusion Serum cTNI,MYO,CK-MB and NT-proBNP are highly expressed in elderly patients with hypertension complicated with heart failure.The combination of the four has a high diagnostic value for hypertension complicated with heart failure.

Numerous c-mesenchymal-epithelial transition (c-MET) inhibitors have been reported as potential anticancer agents. However, most fail to enter clinical trials owing to poor efficacy or drug resistance. To date, the scaffold-based chemical space of small-molecule c-MET inhibitors has not been analyzed. In this study, we constructed the largest c-MET dataset, which included 2,278 molecules with different structures, by inhibiting the half maximal inhibitory concentration (IC₅₀) of kinase activity. No significant differences in drug-like properties were observed between active molecules (1,228) and inactive molecules (1,050), including chemical space coverage, physicochemical properties, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles. The higher chemical diversity of the active molecules was downscaled using t-distributed stochastic neighbor embedding (t-SNE) high-dimensional data. Further clustering and chemical space networks (CSNs) analyses revealed commonly used scaffolds for c-MET inhibitors, such as M5, M7, and M8. Activity cliffs and structural alerts were used to reveal "dead ends" and "safe bets" for c-MET, as well as dominant structural fragments consisting of pyridazinones, triazoles, and pyrazines. Finally, the decision tree model precisely indicated the key structural features required to constitute active c-MET inhibitor molecules, including at least three aromatic heterocycles, five aromatic nitrogen atoms, and eight nitrogen-oxygen atoms. Overall, our analyses revealed potential structure-activity relationship (SAR) patterns for c-MET inhibitors, which can inform the screening of new compounds and guide future optimization efforts.

Objective To construct a patient decision aid(PtDA)for exercise training in pa-tients with chronic obstructive pulmonary disease(COPD)and explore its impacts on decision-making quality of patients' exercise regimens.Methods The development of the PtDA for exercise training in COPD patients was accomplished through literature analysis,the Delphi method,and user surveys,followed by an intervention study.A total of 59 inpatients with COPD were included as study sub-jects.The control group received routine care along with general exercise training guidance,while the intervention group received routine care combined with shared decision-making for exercise training based on the PtDA.The decision conflict and decision preparedness levels of patients in both groups were compared before the intervention and on the day of discharge.The exercise self-efficacy of pa-tients was measured before intervention,on the day of discharge,and 1 month and 3 months after dis-charge.Results The intervention group had significantly lower scores for decision conflict and signif-icantly higher scores for decision preparedness and exercise self-efficacy compared with the control group(P＜0.05).Conclusion The PtDA for exercise training can improve decision conflict and de-cision preparedness in COPD patients,enhance their exercise self-efficacy levels,and provide references for healthcare professionals in improving exercise adherence.

Objective To analyze the differences in oral hygiene and oral microbiota between the patients with schizophrenia and healthy individuals in Baoshan City.Methods 26 patients with schizophrenia from Baoshan Third People's Hospital were selected as the SCZ group and 26 healthy individuals matched by age and BMI as the HC(Healthy control)group.Demographic data,physical indicators,and oral conditions were collected.Saliva samples from 52 subjects were collected and 16S rDNA gene sequencing was used to compare the differences in oral hygiene and oral microbiota between the patients with schizophrenia and the healthy individuals.Results The difference in oral microbial community richness between the SCZ group and the HC group was statistically significant(P<0.05),with the SCZ group containing higher species than the HC group;at the genus level,except for Fusobacterium in the SCZ group and Actinomyces in the HC group,the top 5 dominant bacterial species in both groups were consistent;the results of species difference analysis showed that Fusobacterium and Campylobacter in the SCZ group were higher than those in the HC group(P<0.05).Conclusion The partial dominant bacterial species in the oral cavity of the patients with schizophrenia have changed to sulfate-reducing bacteria that produce hydrogen sulfide.Excessive production of hydrogen sulfide or polysulfide may damage the energy metabolism of mitochondria.